\begin{table}[H]
\centering
\caption{CRISPR-Cas9 Therapeutics in Clinical Development}
\label{tab:crispr_pipeline}
\resizebox{\textwidth}{!}{%
\begin{tabular}{|l|l|l|l|}
\hline
\textbf{Gene Target} & \textbf{Disease Indication} & \textbf{Trial Phase} & \textbf{Key Features} \\
\hline
RPE65 & Leber Congenital Amaurosis 10 (LCA10) & Phase 1 & In vivo retinal editing \\
\hline
ABCA4 & Stargardt Disease & Preclinical & Inherited retinal dystrophy \\
\hline
TTR & Transthyretin Amyloidosis & Phase 1/2 & Systemic neurodegenerative disease \\
\hline
DMD & Duchenne Muscular Dystrophy & Preclinical & Severe progressive muscle degeneration \\
\hline
F8/F9 & Hemophilia A/B & Preclinical & Blood clotting disorders \\
\hline
BCL11A & Sickle Cell Disease (Alternative) & Phase 1 & Fetal hemoglobin reactivation \\
\hline
CFTR & Cystic Fibrosis & Preclinical & Lung disease \\
\hline
SMN1 & Spinal Muscular Atrophy & Preclinical & Neurodegenerative disease \\
\hline
\end{tabular}
}
\end{table}